(Q43551360)

24 November 2017

Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes (English)

1 reference

24 November 2017

1 reference

Göbel H

1

1 reference

24 November 2017

Heinze A

series ordinal

2

1 reference

24 November 2017

Heinze-Kuhn K

series ordinal

3

1 reference

24 November 2017

Lindner V

series ordinal

4

1 reference

24 November 2017

1 March 2001

1 reference

24 November 2017

1 reference

24 November 2017

41

1 reference

24 November 2017

3

1 reference

24 November 2017

264-270

1 reference

Epidemiology of headache in a general population--a prevalence study.

24 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Rizatriptan has central antinociceptive effects against durally evoked responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Rizatriptan, a novel 5-HT1B/1D agonist for migraine: single- and multiple-dose tolerability and pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Rizatriptan: a review of its efficacy in the management of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

A double-blind, placebo-controlled evaluation of the effect of oral doses of rizatriptan 10 mg on oral contraceptive pharmacokinetics in healthy female volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

Coronary side-effect potential of current and prospective antimigraine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1526-4610.2001.111006264.X

10.1046/J.1526-4610.2001.111006264.X

21 January 2018

Identifiers

DOI

1 reference

24 November 2017

1 reference